228 related articles for article (PubMed ID: 17404325)
21. Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement.
Kusner LL; Sengupta M; Kaminski HJ
Ann N Y Acad Sci; 2018 Feb; 1413(1):136-142. PubMed ID: 29356015
[TBL] [Abstract][Full Text] [Related]
22. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis.
Goluszko E; Hjelmström P; Deng C; Poussin MA; Ruddle NH; Christadoss P
J Neuroimmunol; 2001 Feb; 113(1):109-18. PubMed ID: 11137582
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.
Martínez-Martínez P; Losen M; Duimel H; Frederik P; Spaans F; Molenaar P; Vincent A; De Baets MH
Am J Pathol; 2007 Feb; 170(2):644-57. PubMed ID: 17255332
[TBL] [Abstract][Full Text] [Related]
24. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
[TBL] [Abstract][Full Text] [Related]
25. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
[TBL] [Abstract][Full Text] [Related]
26. Prevention of passively transferred experimental autoimmune myasthenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor.
Papanastasiou D; Poulas K; Kokla A; Tzartos SJ
J Neuroimmunol; 2000 May; 104(2):124-32. PubMed ID: 10713351
[TBL] [Abstract][Full Text] [Related]
27. Clonotypic analysis of anti-acetylcholine receptor antibodies from experimental autoimmune myasthenia gravis-sensitive Lewis rats and experimental autoimmune myasthenia gravis-resistant Wistar Furth rats.
Zoda T; Yeh TM; Krolick KA
J Immunol; 1991 Jan; 146(2):663-70. PubMed ID: 1987281
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis.
Im SH; Barchan D; Fuchs S; Souroujon MC
J Neuroimmunol; 2000 Nov; 111(1-2):161-8. PubMed ID: 11063834
[TBL] [Abstract][Full Text] [Related]
29. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
30. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
31. Animal models of myasthenia gravis.
Christadoss P; Poussin M; Deng C
Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
[TBL] [Abstract][Full Text] [Related]
32. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
Loutrari H; Kokla A; Tzartos SJ
Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis.
Gomez CM; Richman DP
J Immunol; 1985 Jul; 135(1):234-41. PubMed ID: 3873489
[TBL] [Abstract][Full Text] [Related]
34. Experimental autoimmune myasthenia gravis in naive non-obese diabetic (NOD/LtJ) mice: susceptibility associated with natural IgG antibodies to the acetylcholine receptor.
Quintana FJ; Pitashny M; Cohen IR
Int Immunol; 2003 Jan; 15(1):11-6. PubMed ID: 12502721
[TBL] [Abstract][Full Text] [Related]
35. Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.
Luo J; Kuryatov A; Lindstrom JM
Ann Neurol; 2010 Apr; 67(4):441-51. PubMed ID: 20437579
[TBL] [Abstract][Full Text] [Related]
36. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
37. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
[TBL] [Abstract][Full Text] [Related]
38. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
39. IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.
Yang H; Tüzün E; Alagappan D; Yu X; Scott BG; Ischenko A; Christadoss P
J Immunol; 2005 Aug; 175(3):2018-25. PubMed ID: 16034147
[TBL] [Abstract][Full Text] [Related]
40. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
Araga S; LeBoeuf RD; Blalock JE
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
